vimarsana.com

Page 17 - மைய மருந்து தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Welcome To IANS Live - NATION - No vaccine approval yet, drug regulator analysing SII, Bharat Biotech data

Photo Credit: IANS IANSLive New Delhi, Dec 30 (IANS) The analysis of the additional data and information submitted by Serum Institute of India (SII) and Bharat Biotech is still being conducted by regulator Central Drug Standard Control Organisation s (CDSCO) Subject Expert Committee and their next meeting will be held on January 1. To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action. For news, views and gossips, follow IANS at Twitter. Update: 30-December-2020

COVID-19 vaccine in India: Emergency use authorisation still not approved; SEC to reconvene on Jan 1

PM Narendra Modi reviewed the development of COVID-19 vaccine candidate ZyCOV-D in Ahmedabad. The analysis of the additional data and information submitted by Serum Institute of India (SII) and Bharat Biotech is still being conducted by regulator Central Drug Standard Control Organisation s (CDSCO) Subject Expert Committee and their next meeting will be held on January 1. The Subject Expert Committee met on Wednesday to consider the Emergency Use Authorisation (EUA) request of Pfizer, SII and Bharat Biotech Private Ltd. Further time was requested on behalf of Pfizer, while the additional data and information presented by the SII and Bharat Biotech was perused and analysed by the SEC.

Covaxin produces robust immune response with no serious adverse events, show Phase 1 results

In the Phase 1 study, which is being jointed conducted by the ICMR, the researchers have said the reactogenicity “was absent in the majority of participants, with mild events”. And on immune response, the researchers concluded that both “robust humoral and cell-mediated responses were observed”. “…this study has several strengths. To ensure generalizability, this study was conducted with participants from diverse geographic locations and socioeconomic conditions, enrolling 375 participants across 11 hospitals. Despite the fact that enrollment occurred during a national lockdown, which led to several operational challenges, the overall participant retention rate was 97%. The sample size was intentionally large to enable the inference of meaningful conclusions regarding immunogenicity and safety,” the researchers concluded.

Global Ventilator Market Analysis and Forecast, 2021-2030: Market to Reach $3,110 Million by the End of 2020 Due to COVID-19 Pandemic

Share: ResearchAndMarkets.com s offering. Global Ventilator Market to Reach $3,110 Million by the End of 2020 Due to COVID-19 Pandemic The global ventilator market is witnessing an exponential rise in the size of the market due to the ongoing COVID-19 pandemic. The overall market was estimated to be $1,072 million in FY 2018, and it was expected to grow at a CAGR of 7.1% in the pre-COVID scenario. However, the COVID-19 pandemic has resulted in an extensive rise in the ventilator demand and has increased the growth rate by up to 172% in 2020. Presently, more than 45 companies are operating in this market, including already exiting healthcare companies and emerging non-healthcare companies.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.